Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors.

The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors.

Study Overview

• Status: Recruiting
• Conditions: Advanced Solid Tumors; Metastatic Solid Tumors
• Intervention / Treatment: Biological: Pembrolizumab; Drug: MK-0472; Drug: MK-1084

• Study Type: Interventional
• Enrollment (Estimated): 178
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Toll Free Number; Phone Number: 1-888-577-8839; Email: Trialsites@msd.com

Study Locations

• Canada
  • Ontario
    • Toronto, Ontario, Canada, M5G 2M9
      • Recruiting
      • Princess Margaret Cancer Centre ( Site 0101)
      • Contact: Study Coordinator; Phone Number: 416 946 4501 x5083
  • Quebec
    • Montreal, Quebec, Canada, H2X 0A9
      • Recruiting
      • Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0100)
      • Contact: Study Coordinator; Phone Number: 5148908000x30921
    • Montreal, Quebec, Canada, H3T 1E2
      • Recruiting
      • Jewish General Hospital ( Site 0104)
      • Contact: Study Coordinator; Phone Number: 5143408222
• Chile
  • Region M. de Santiago
    • Santiago, Region M. de Santiago, Chile, 7500653
      • Recruiting
      • Centro de Estudios Clínicos SAGA ( Site 0701)
      • Contact: Study Coordinator; Phone Number: +56991612199
    • Santiago, Region M. de Santiago, Chile, 7500921
      • Recruiting
      • Fundacion Arturo Lopez Perez ( Site 0700)
      • Contact: Study Coordinator; Phone Number: 56224205098
    • Santiago, Region M. de Santiago, Chile, 8330034
      • Recruiting
      • Centro de Investigacion Clinicadela Universidad Catolica ( Site 0703)
      • Contact: Study Coordinator; Phone Number: 56934331806
    • Santiago, Region M. de Santiago, Chile, 8420383
      • Recruiting
      • Bradfordhill ( Site 0702)
      • Contact: Study Coordinator; Phone Number: +56229490970
• Israel
  • Haifa, Israel, 3109601
    • Recruiting
    • Rambam Health Care Campus ( Site 0304)
    • Contact: Study Coordinator; Phone Number: 97247776234
  • Jerusalem, Israel, 9103102
    • Recruiting
    • Shaare Zedek Medical Center ( Site 0303)
    • Contact: Study Coordinator; Phone Number: 97225641600
  • Petah Tikva, Israel, 4941492
    • Recruiting
    • Rabin Medical Center ( Site 0301)
    • Contact: Study Coordinator; Phone Number: 97239378110
  • Ramat Gan, Israel, 5265601
    • Recruiting
    • Sheba Medical Center ( Site 0300)
    • Contact: Study Coordinator; Phone Number: +9725304498
  • Tel Aviv, Israel, 6423906
    • Recruiting
    • Sourasky Medical Center ( Site 0302)
    • Contact: Study Coordinator; Phone Number: 97236973082
• Poland
  • Masovian Voivodeship
    • Warsaw, Masovian Voivodeship, Poland, 02-781
      • Recruiting
      • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0401)
      • Contact: Study Coordinator; Phone Number: +48225463381
  • Pomeranian Voivodeship
    • Gdansk, Pomeranian Voivodeship, Poland, 80-214
      • Recruiting
      • Uniwersyteckie Centrum Kliniczne ( Site 0400)
      • Contact: Study Coordinator; Phone Number: +48585844466
• Spain
  • Barcelona, Spain, 08035
    • Recruiting
    • Hospital Universitari Vall d'Hebron ( Site 0500)
    • Contact: Study Coordinator; Phone Number: +34 93 274 60 00
  • Seville, Spain, 41013
    • Recruiting
    • Hospital Virgen del Rocio ( Site 0503)
    • Contact: Study Coordinator; Phone Number: +34955013068
  • Catalonia
    • L'Hospitalet de Llobregat, Catalonia, Spain, 08907
      • Recruiting
      • Institut Català d'Oncologia - L'Hospitalet-Medical Oncology ( Site 0501)
      • Contact: Study Coordinator; Phone Number: +34 93 260 77 44
  • Madrid, Comunidad de
    • Madrid, Madrid, Comunidad de, Spain, 28050
      • Recruiting
      • Centro Integral Oncologico Clara Campal-Hospital HM Universitario Sanchinarro-START Madrid, ( Site 0504)
      • Contact: Study Coordinator; Phone Number: +34917567984
• Switzerland
  • Canton Ticino
    • Bellinzona, Canton Ticino, Switzerland, 6500
      • Recruiting
      • Ospedale Regionale Bellinzona e Valli ( Site 0200)
      • Contact: Study Coordinator; Phone Number: +41918119510
  • Canton of Geneva
    • Geneva, Canton of Geneva, Switzerland, 1211
      • Recruiting
      • Hôpitaux Universitaires de Genève (HUG) ( Site 0202)
      • Contact: Study Coordinator; Phone Number: +41223729881
  • Canton of St. Gallen
    • Sankt Gallen, Canton of St. Gallen, Switzerland, 9000
      • Recruiting
      • Cantonal Hospital St.Gallen-Oncology & Hematology ( Site 0201)
      • Contact: Study Coordinator; Phone Number: +417149410 99
• United States
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Recruiting
      • Northwestern Memorial Hospital ( Site 0002)
      • Contact: Study Coordinator; Phone Number: 312-926-8105
  • Kentucky
    • Louisville, Kentucky, United States, 40202
      • Recruiting
      • The University of Louisville, James Graham Brown Cancer Center ( Site 0004)
      • Contact: Study Coordinator; Phone Number: 502-562-3429
  • New Jersey
    • Hackensack, New Jersey, United States, 07601
      • Recruiting
      • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0001)
      • Contact: Study Coordinator; Phone Number: 551-996-1777
    • New Brunswick, New Jersey, United States, 08901
      • Recruiting
      • Rutgers Cancer Institute of New Jersey ( Site 0005)
      • Contact: Study Coordinator; Phone Number: 732-235-2465

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

• Has histologically or cytologically confirmed solid tumor by pathology report that is advanced/metastatic
• Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to study enrollment
• Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening
• Participants with human immunodeficiency virus (HIV) infection must have well controlled HIV on stable (>4 weeks) antiretroviral therapy (ART)
• Arm 1: Oncogenic receptor tyrosine kinase (RTK) pathway alterations confirmed by a historical report or local testing (tissue or blood) and have received, or been intolerant to, all available treatment known to confer clinical benefit
• Arm 2: Tumor types known to be sensitive to anti-programmed cell death 1 protein (PD-1)/ligand 1 (L1) therapies are eligible. Tumor types permitted include: melanoma, non-small cell lung cancer (NSCLC) without epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK)/ROS1 mutations, renal cell carcinoma, urothelial carcinoma, Merkel cell carcinoma, MSI-high CRC, endometrial cancer, cervical cancer, small cell lung cancer, triple negative breast cancer, esophageal cancer, gastric cancer, biliary tract cancer, hepatocellular carcinoma, head and neck squamous cancer, cutaneous squamous cancer, anal squamous cancer, and mesothelioma
• Arm 3: Has histologically OR blood-based confirmation of Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutation

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

• Has not recovered to common terminology criteria for adverse events (CTCAE) Grade 1 or better from any adverse events that were due to cancer therapeutics administered more than 4 weeks earlier. Participants receiving ongoing replacement hormone therapy for endocrine immune-related AEs will not be excluded from participation in this study
• Has history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years
• History of hyperparathyroidism or hypercalcemia
• Has one or more of the following ophthalmological findings/conditions: a) Intraocular pressure >21 mm Hg and/or any diagnosis of glaucoma b) Diagnosis of central serous retinopathy, retinal vein occlusion, or retinal artery occlusion and c) Diagnosis of retinal degenerative disease
• Has clinically significant cardiovascular disease
• Bullous exfoliative skin disorders of any grade
• Known hypersensitivity to MK-0472, MK-1084, or pembrolizumab, or any of their excipients
• Received therapy with a proton-pump inhibitor or an H2 histamine blocker receptor antagonist within 7 days before the first scheduled day of study dosing
• Has discontinued prior therapy with an anti-programmed cell death-1 (PD-1), anti-programmed death-ligand 1 (PD-L1), or anti-programmed death-ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor due to an adverse event
• Received prior systemic anticancer therapy including investigational agents within 4 weeks before first dose
• Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
• Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration
• Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication
• Has known additional malignancy that is progressing or has required active treatment within the past 2 years
• Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable for at least 4 weeks as confirmed by repeat imaging performed during the study screening, are clinically stable and have not required steroid treatment for at least 14 days before the first dose of study intervention
• Has active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy
• Has history of pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
• Has active infection requiring systemic therapy
• Has history of allogeneic tissue/solid organ transplant
• Have not adequately recovered from major surgery or have ongoing surgical complications

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: MK-0472; Participants receive MK-0472 via oral capsule according to one of the protocol-specified dosing regimens until disease progression or withdrawal/discontinuation.	Drug: MK-0472; Oral Administration
Experimental: MK-0472 + Pembrolizumab; Participants receive MK-0472 via oral capsule according to one of the protocol-specified dosing regimens until disease progression or withdrawal/discontinuation, plus pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).	Biological: Pembrolizumab; IV infusion; Other Names: MK-3475; Keytruda®; Drug: MK-0472; Oral Administration
Experimental: MK-0472 + MK-1084; Participants receive MK-0472 via oral capsule according to one of the protocol-specified dosing regimens, plus MK-1084 via oral capsule until disease progression or withdrawal/discontinuation.	Drug: MK-0472; Oral Administration; Drug: MK-1084; Oral Administration

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants Who Experience a Dose Limiting Toxicity (DLT) as Assessed Using Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0	DLT will be defined as any drug-related AE observed during the DLT evaluation period (e.g. Cycle 1) that results in a change to a given dose or a delay in initiating the next cycle.	At the end of Cycle 1 (each cycle is 21 days)
Number of Participants Who Experience One or More Adverse Events (AEs)	An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience one or more AE's will be reported.	Up to approximately 56 months
Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)	An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study treatment due to an AE will be reported.	Up to approximately 56 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Lowest Plasma Concentration (Ctrough) of MK-0472	Blood samples will be collected at specified intervals for the determination of Ctrough. Ctrough is defined as the lowest concentration of MK-0472 reached before the next dose is administered.	At predetermined timepoints Predose up to Cycle 6 (Each cycle length = 21 Days)
Area Under the Concentration Time-curve From Time 0 to the End of the Dosing Period (AUCtau) of MK-0472	Blood samples will be collected at specified intervals for the determination of AUCtau. AUCtau is defined as the area under concentration-time curve from 0 to the end of the dosing period.	At predetermined timepoints predose and postdose up to Cycle 6 (Each cycle length = 21 Days)
Maximum Plasma Concentration (Cmax) of MK-0472	Blood samples will be collected at specified intervals for the determination of Cmax. Cmax is defined as the maximum concentration of MK-0472 reached.	At predetermined timepoints postdose up to Cycle 6 (Each cycle length = 21 Days)

Collaborators and Investigators

• Sponsor: Merck Sharp & Dohme LLC
• Investigators: Study Director: Medical Director, Merck Sharp & Dohme LLC

Publications and helpful links

Helpful Links

• Merck Clinical Trials Information
• Plain Language Summary

Study record dates

Study Major Dates

• Study Start (Actual): July 6, 2023
• Primary Completion (Estimated): February 12, 2028
• Study Completion (Estimated): February 12, 2028

Study Registration Dates

• First Submitted: May 2, 2023
• First Submitted That Met QC Criteria: May 2, 2023
• First Posted (Actual): May 10, 2023

Study Record Updates

• Last Update Posted (Actual): March 13, 2026
• Last Update Submitted That Met QC Criteria: March 12, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: Programmed Cell Death-1 (PD1, PD-1); Programmed Death-Ligand 1 (PDL1, PD-L1); Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP-2)
• Additional Relevant MeSH Terms: Parkinson Disease 4, Autosomal Dominant Lewy Body; Antineoplastic Agents, Immunological; Immune Checkpoint Inhibitors; Antineoplastic Agents; Molecular Mechanisms of Pharmacological Action; pembrolizumab
• Other Study ID Numbers: 0472-001; MK-0472-001 (Other Identifier: MSD); U1111-1310-1179 (Registry Identifier: UTN); 2024-516006-32-00 (Registry Identifier: EU CT)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No